echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > 2020ESMO China Light Hengrui Pharmaceuticals a number of research results played the strongest sound of domestic original research drugs.

    2020ESMO China Light Hengrui Pharmaceuticals a number of research results played the strongest sound of domestic original research drugs.

    • Last Update: 2020-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    As a pioneer and leader in china's innovative drug research and development, Hengrui Pharmaceuticals has once again made its international landing in the field of digestive tract tumors, lung cancer, osteosarcoma, breast cancer, head and neck tumors, blood tumors, gynecological tumors and other fields.
    , let's take a look at what research is coming! Lung cancer ACTIVE: Apatinib plus gefitinib versusplacebo plus gefitinib as first-line treatment for advanced non-squamous non-small-cell cell patients with activating EGFR mutations: a multicentered, Randomized, double-blind, placebo-controlled phase IIItrial (CTONG1706) methyroidate apatinib first-line joint gyfetinib treatment late EGFR mutation NSCLC Phase III clinical study Form: LBA Speaker: Zhangli —————————————————————————————————— —————————————————— 1267P - Efficacy of camrelizumab (SHR-1210) plus apatinib as second-line treatment for advanced squamous NSCLC Karelli pearl single-anti-joint Apatini second-line treatment late scaly NSCLC Report form: E-Poster Speaker: Guanghui Gao (Shanghai, China) Date: 2020/09/17 ———————————————————————————————————————————————————— 1366P - Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with. EGFR-TKI resistance (date updated) Apatini combined EGFR-TKI treatment EGFR-TKI drug resistance after late NSCLC (data update) Report form: E-Poster Speaker: Ruifen Tian (Taiyuan, China) Date: 2020/09/17 ———————————————————————————————————————————————————— 1804P - The Efficacy of Apatinib plus Topotecan as Laterline Therapy for Advanced Cell Lung Cancer Apatini Combined Topology As a Late Cell Lung Cancer Post-Treatment Efficacy Report Form: E-Poster Speaker: Haifeng Qin (Beijing, China) Date: 2020/09/17 ———————————————————————————————————————————————————— 1805P -Apatinib combined with irinotecan in the treatment of small cell cell: cancer 2, Single-arm, prospective study Appatini jointly treats small cell lung cancer: Phase II, single arm, prospective study Report form: E-Poster Speaker: Yanbin Zhao (Harbin, China) Date: 2020/09/17 Hepatocellular Carcinoma 983P - Camrelizumab (C) in combination with apatinib (A) patient. Hepatocellular carcinoma (RESCUE): an open-label, multi-center, phase 2 trial. Karelli-Juju monoantigenated apatinist for the treatment of advanced hepatocellular carcinoma (RESCUE): Open Label, Multi-Center, Phase II Study Form: E-Poster Speaker: Jianming Xuming (Beijing, China) Date: 2020/09/17 ———————————————————————————————————————————————————— 985P - A phase 2 study of camrelizumab for advanced hepatocellular carcinoma: two-year outcomes and continued beyond treatment RECIST-defined progression. Karelli Juju single anti-treatment of advanced hepatocellular carcinoma Phase II study: RECIST defines progress after continuous treatment for 2 years Results Report form: E-Poster Speaker: Zhenggang Ren (Shanghai, China) Date: 2020/09/17 ———————————————————————————————————————————————————— 81TiP - The changes of immune functionand prognosis in advanced perihilarcholangiocarcinoma patients by immunotherapycombined with different topical therapies immunotherapy in combination with other types of treatment of patients with advanced hepatocyte bile duct cell carcinoma patients immune function and prognosis. Report Form: E-Poster Speaker: Chao Zhao (Taiyuan, China) Date: 2020/09/17 Gastric Cancer 1452P - Phase I study of apatinib plus POF (paclitaxel plus FOLFOX) in patients (paclitaxel plus FOLFOX) in patients (pts) with treatment-naïve advanced gastric cancer (TNAGC), the results of a Phase I study on the treatment of patients with advanced gastric cancer (TNAGC) at 850mg Apatini combined POF (Yew alcohol and FOLFOX), including results from 850mg dose Report form: E-Poster Speaker: Fuzhou, Fujian, China) Date: 2020/09/17 ——— ————————————————————————————————————————————————— 1455P - Single-arm, open-label, prospective, multicenter study of apatinib combined with chemotherapy as second-line therapy in patients with advanced gastric apatini combined chemotherapy second-line treatment of patients with advanced gastric apatini, open label, forward-looking, multi-center study Report form: E-Poster Speaker: Jifeng Feng (China) Date: 2020/09/17 ——————————————————————————————————————————————— ————— 1428P - Apatinib combined with docetaxelin second-line treatment of advanced gastriccancer: a prospective clinical study (data updated) Apatini combined with Dorsey second-line treatment for advanced stomach cancer: forward-looking clinical study (data update) Report form: E-Poster Speaker: Mudan Yang (Taiyuan, China) Date: 2020/09/17 ———————————————————————————————————————————————————— 1434P - Aive prospect, multicenter, nonrandomized, controled trial of of. Apatinibplus perioperative chemotherapy with FLOTprotocol and surgery for the treatment of stage III gastric cancer Apatini joint FLT program perioperative chemotherapy and surgical treatment phase III gastric cancer prospective multi-center non-randomized controlled study Form: E-Poster Speaker: Junnyang (Shenyang, China) Date: 2020/09/17 ———————————————————————————————————————————————————— 442P - Camrelizumab combined with with Apatinibin the treatment of patients with advancedgastric. cancer and colorectal cancer: One-armexploratory clinical trial Carelli pearl single anti-combination apatini to treat advanced stomach and colorectal cancer: one-arm exploratory clinical study Report form: E-Poster Speaker: Li (Xiamen, China) Date: 2020/09/17 ———————————————————————————————————————————————————— 1427P - A phase II study of neoadjuvantcurrent conchemoradiotherapy with apatinib for HER-2negative Siewert type II and III adenocarcinomaof esophagogastric. Junction New Assisted Synchritis Chemotherapy Combined with Apatini to Treat Siewert TYPE II, TYPE III. HER2 Negative Gastroesophageal Junction Adenocarcinoma Phase II Clinical Study Form: E-Poster Speaker: Shijiazhuang, China) Date: 2020/09/17 Esophageal Cancer 1431P - Study on safety and efficacyof apatinib combined with concurrentchemoradiotherapy in the treatment of non-excisive esophageal cancer Apatini combined with chemotherapy Treatment of non-excisive esophageal cancer Report form: E-Poster Speaker: Jingping Yu China) Date: 2020/09/17 ——— ————————————————————————————————————————————————— 1501TiP - The changes of tumor immunemicroenvironment in esophageal squamouscell carcinoma patients by different new aids to treat esophageal squapies cancer tumor immuno-microenvironment Changes Report form: E-Poster Speaker: Wei Li Wang (Taiyuan, China) Date: 2020/09/17 ———————————————————————————————————————————————————— 1034P - Camrelizumab in. The Treatmentof Patients wi.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.